Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHF 6001 in adolescent and adult asthma patients
NCT06900816Phase 2Completed
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Start
- Mar 2025
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tanimilast in asthma, sponsored by Chiesi Farmaceutici S.p.A.. Started Mar 2025; status: completed.
02
Drugs
tanimilast
03
Conditions
asthma
Beyond the preview
Go deeper on NCT06900816.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06900816.